Journal of Medical Economics
Volume 25, 2022 - Issue 1
Diabetes
Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis
Jean-François Yalea Department of Medicine, McGill University Health Center, McGill University, Montréal, Canada
https://orcid.org/0000-0002-7833-9050
https://orcid.org/0000-0002-7833-9050, Beatrice Osumilib Eli Lilly and Company Limited, Bracknell, UKCorrespondence[email protected]
https://orcid.org/0000-0002-5862-9325
https://orcid.org/0000-0002-5862-9325, Beth D. Mitchellc Eli Lilly and Company, Indianapolis, IN, USAhttps://orcid.org/0000-0002-8583-6303
https://orcid.org/0000-0002-8583-6303, Barnaby Huntd Ossian Health Economics and Communications, Basel, Switzerlandhttps://orcid.org/0000-0001-5420-279X
https://orcid.org/0000-0001-5420-279X, Gurjeev Sohie Eisai Limited, Mississauga, Canadahttps://orcid.org/0000-0003-0808-2939
https://orcid.org/0000-0003-0808-2939, , & show all